Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study

Kathleen M. Wesa, Susanna Cunningham-Rundles, Virginia M. Klimek, Emily Vertosick, Marci I. Coleton, K. Simon Yeung, Hong Lin, Stephen D Nimer, Barrie R. Cassileth

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Background: Myelodysplastic syndromes (MDS) are characterized by ineffective erythropoiesis with dysplastic bone marrow leading to peripheral cytopenia, risk of infection, and progression to acute myelogenous leukemia. Maitake mushroom beta-glucan, a dietary supplement, stimulates hematopoietic progenitor cell differentiation, granulocyte colony-stimulating factor production, and recovery of peripheral blood leukocytes after bone marrow injury. This phase II trial examined the effects of Maitake on innate immune function in MDS.

Methods: Myelodysplastic syndromes patients with International Prognostic Scoring System Low- and Intermediate-1-risk disease received oral Maitake extract at 3 mg/kg twice daily for 12 weeks. Primary endpoints included neutrophil count and function tested as endogenous or stimulated neutrophil production of reactive oxygen species (ROS) by flow cytometry compared with age-matched healthy controls (HC). ROS activators were Escherichiacoli, phorbol ester, and the bacterial peptide N-formylmethionyl-leucyl-phenylalanine (fMLP). Complete blood counts, chemistry panels, iron studies, and monocyte function were evaluated.

Results: Of 21 patients enrolled, 18 completed the study and were evaluable. Maitake increased endogenous (basal) neutrophil (p = 0.005) and monocyte function (p = 0.021). Pre-treatment monocyte response to E. coli was reduced in MDS patients compared with HC (p = 0.002) and increased (p = 0.0004) after treatment. fMLP-stimulated ROS production response also increased (p = 0.03). Asymptomatic eosinophilia occurred in 4 patients (p = 0.014). Other changes in albumin, hemoglobin, and total protein were not clinically relevant.

Conclusions: Maitake was well tolerated. Enhanced in vitro neutrophil and monocyte function following treatment demonstrate that Maitake has beneficial immunomodulatory potential in MDS. Further study is warranted.

Original languageEnglish
Pages (from-to)237-247
Number of pages11
JournalCancer Immunology, Immunotherapy
Volume64
Issue number2
DOIs
StatePublished - 2014

Keywords

  • Beta-glucan
  • Infections
  • Maitake
  • Monocyte
  • Myelodysplastic syndrome
  • Neutrophil

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study'. Together they form a unique fingerprint.

  • Cite this

    Wesa, K. M., Cunningham-Rundles, S., Klimek, V. M., Vertosick, E., Coleton, M. I., Yeung, K. S., Lin, H., Nimer, S. D., & Cassileth, B. R. (2014). Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study. Cancer Immunology, Immunotherapy, 64(2), 237-247. https://doi.org/10.1007/s00262-014-1628-6